Novavax Stock: Fluctuations, Soaring, Short Selling, and Trending with Trump's SPAC Partner

Novavax shares fell over 8% after a previous surge in price following the FDA's Emergency Use Authorization for the company's updated protein-based COVID-19 vaccine for individuals aged 12 and older. The pullback in stock comes as the FDA has also approved updated vaccines from Moderna and Pfizer-BioNTech for the fall, all of which are expected to provide protection against current strains of the virus.